IRVINE, CA–(Marketwired – Nov 28, 2017) – Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that its research staff is nearing completion of a novel new cannabinoid formulary to treat the Asthma and Chronic Obstructive Pulmonary Disease (COPD) Overlap Syndrome (ACOS) with clinical trials to follow upon completion.
“Our recent development of our MDI and Rescue Inhaler medications for these patients in part is the reason this research evolved to treat this under-diagnosed syndrome. While our formulations for these medications achieve the desired effects for the illness targeted as a rescue medication they cannot treat effectively the diagnosis of the Overlap Syndrome. More interesting is the prevalence of ACOS observed among populations of patients diagnosed with COPD.
Our new formulary will target four aspects of this illness inflammation, airway constriction, capacity, and anxiety. Cannabinoid extracts have many unique properties as well as